Urolithin A Trials Show Why Muscle Endpoints Matter

On 2026-10-15, Ones published an article reviewing human urolithin A trials, including a 2022 randomized study by Liu et al. in JAMA Network Open. That older study provides a useful retrospective test of how muscle findings become healthy-aging claims.

Human trials report specific muscle and mitochondrial signals

Published summaries of the 2022 trial describe 66 adults aged 65 to 90 who received 1,000 mg/day of urolithin A or placebo for four months. Selected hand- and leg-muscle endurance measures improved, alongside changes in mitochondrial-health biomarkers. The primary endpoints were six-minute walk distance and maximal ATP production in hand muscle, and neither differed significantly from placebo. For healthspan research, this is a mixed finding: signals in particular measurements rather than consistent improvement across the trial’s main tests.

Evidence type: Human randomized trials, including an older-adult placebo-controlled study.

Mitochondrial recycling is the proposed biological link

Ones describes urolithin A as supporting mitochondrial recycling, known as mitophagy. This is the biological rationale connecting the compound to the mitochondrial measurements discussed in the human studies. The article characterizes mitochondrial biomarkers and muscle endurance as the areas with the strongest human evidence.

Those are related subjects, but they sit at different points in the research question. The proposed mechanism concerns a cellular process. The biomarkers concern biological measurements, while the endurance tests concern performance under specific study conditions. Keeping those categories separate prevents the explanation of a mechanism from replacing the description of a result.

Background on how cells maintain mitochondrial quality helps place this hypothesis in context. Here, mitophagy is the proposed biological link discussed by Ones. The human findings are best described using the actual measurements collected rather than a broad label such as mitochondrial rejuvenation.

Different measurements answer different questions

The most useful reading starts with the outcome rather than the ingredient. A muscle-endurance finding addresses performance in the tested muscle task. A walking-distance finding addresses walking performance. A mitochondrial biomarker describes a biological signal.

These categories belong in the same evidence discussion without being treated as interchangeable. Preserving the names of the endpoints gives readers the information needed to judge the scope of a claim. Describing all of them simply as better mitochondrial health removes distinctions that matter to the interpretation.

The central question is therefore how closely the language of a claim matches the measurement behind it. “Selected muscle-endurance measures improved” is a more precise account than “physical function improved.” The same principle applies when reading aging-related biomarkers in context: the measurement should remain visible in the explanation.

Food-derived production provides a separate piece of context

Ones also connects dietary ellagitannins with the body’s production of urolithin A. It names pomegranates, walnuts and raspberries as food sources of those compounds. According to the article, production varies with gut microbiome composition.

This dietary context addresses where urolithin A can come from, whereas the supplement trials address what happened after a defined intervention. Those are different research questions. A food-source explanation belongs in the biological background, while the randomized comparisons belong in the assessment of the supplement’s effects.

Study design and source quality set the boundaries

• The older-adult study was modest in size and duration. Its cohort and follow-up support an assessment of the outcomes measured during that intervention. They provide a narrower basis for claims about sustained changes across later life. The practical implication is to keep the study population and observation period attached to any description of benefit rather than presenting the result as a general property of the supplement.
• The Ones article appears to misidentify the older-adult trial. It calls the study a Nature Aging trial and describes muscle endurance as its primary outcome. The available summaries instead identify Liu et al. in JAMA Network Open and distinguish the primary outcomes from the selected endurance findings. That correction matters because a positive secondary result should retain its secondary status when the study is summarized.
• The earlier proof-of-concept account uses a different comparison. Ones describes a 2019 study involving 40 healthy middle-aged adults taking 500 mg/day for 12 weeks. It reports changes in cardiorespiratory fitness and plasma acylcarnitines against baseline rather than providing a placebo comparison in its summary. A change from a participant’s starting measurement answers a different question from a difference between treatment and placebo groups. The two descriptions should not be substituted for one another.
• The trials involve distinct age groups. A separate randomized study is cited by Ones as Singh et al. in Cell Reports Medicine in 2022. Its summary describes middle-aged adults receiving 500 or 1,000 mg/day for four months. Those details identify the intervention studied rather than a recommended regimen. Findings from middle-aged and older-adult populations should remain linked to their respective studies rather than being pooled into an undefined claim about adults generally.
• The broader longevity outcomes remain unestablished. Ones notes that human trials have not established lifespan extension, reversal of neurodegeneration or dramatic muscle-mass gains. This is a boundary on the available evidence rather than proof that the compound has no possible effect on those outcomes. A supplement claim about any of these subjects would need evidence addressing that particular outcome rather than borrowing support from the muscle or biomarker findings.
• Greater absorption is a different finding from greater benefit. Ones cites a pharmacokinetic study in which a high-fat meal increased plasma exposure to urolithin A by about 2.5-fold. That figure describes measured exposure, not a corresponding improvement in endurance or health. It should remain attached to the absorption question. Recasting it as a multiplier for clinical benefits would change both what was measured and what the result means.
• The suggested time of day is not supported by an outcome comparison. Ones recommends morning or lunchtime use, but describes the morning rationale as based on estimated absorption timing. Its summary does not provide a clinical comparison showing better health outcomes from morning rather than evening use. This separates a proposed timing rationale from a finding about the effectiveness of a schedule; the article’s practical suggestion should not be presented as a trial result.
• The publisher has a disclosed commercial interest. Ones says it formulates and sells personalized supplements that may include ingredients discussed in its content. It also states that urolithin A is not currently sold by Ones as a standalone ingredient. This disclosure does not by itself invalidate the article’s account. It does give readers a reason to distinguish its supplement-use recommendations from the findings attributed to the randomized studies.

For someone evaluating a supplement claim, the practical response is to make the claim match the study. Check whether the result was primary or secondary and whether the comparison was against placebo or the participant’s own baseline. Keep the tested population and follow-up attached to the finding. These questions offer a more reliable framework than treating every favorable measurement as equivalent evidence.

The broader challenge of judging how longevity findings translate to people also starts with identifying the evidence type. In this case, human trials are available and deserve close reading on their own terms. Decisions about personal supplement use belong in a discussion with a qualified healthcare professional rather than being inferred from a biomarker headline.

Longer human trials should test sustained functional benefits

The next useful phase is larger, longer randomized human research with prespecified functional outcomes that tests whether the reported muscle and mitochondrial signals translate into sustained benefits relevant to healthy aging.

How AgeAmaze helps

Urolithin A coverage puts evidence classification on a research editor’s desk; with AgeAmaze, the distinction between human and animal findings becomes part of the explanation. Its research-led reporting connects mechanisms to the populations studied so skeptical adults can assess emerging interventions without confusing preclinical promise with demonstrated human benefit.

Read the research

Sources

1. Urolithin A vs NMN: Which Has Better Human Evidence?
2. ones.health · blog · when-to-take-urolithin-aWhen to Take Urolithin A for Best Results | Ones